SCHEMBL6894742

SCHEMBL6894742

CC(C)(O)CCC(P(=O)(O)O)P(=O)(O)O

nearest known ligand 0.52

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
FDPS P14324 7/20 0.52
ALDH1A1 P00352 1/20 0.41
GRM4 Q14833 1/20 0.38
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6898328 0.80 FDPS (0.46) FDPSGRM4LMNA
SCHEMBL6892102 0.79 FDPS (0.45) FDPSGRM4LMNA
SCHEMBL6893873 0.79 FDPS (0.45) FDPSGRM4LMNA
SCHEMBL6894688 0.79 FDPS (0.45) FDPSGRM4LMNA
SCHEMBL6897050 0.79 FDPS (0.45) FDPSGRM4LMNA
SCHEMBL10785210 0.73 FDPS (0.67) FDPS
SCHEMBL10257119 0.71 ALDH1A1 (0.53) ALDH1A1
SCHEMBL10263719 0.70 SMPD1 (0.36) FDPSALDH1A1
SCHEMBL10654239 0.70 FDPS (0.44) FDPSLMNA
SCHEMBL4095556 0.69 FDPS (1.00) FDPS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1165573-B1 COMPOUNDS SELECTIVELY INHIBITING GAMMA 9 DELTA 2 T LYMPHOCYTES INST NAT SANTE ETDE LA RECH ME (FR) 2004-01-21 EP disclosed
US-20040009123-A1 Compounds selectively inhibiting gamma 9 delta 2 T lymphocytes INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2004-01-15 US disclosed
US-20040006131-A1 Compounds selectively inhibiting gamma 9 delta 2 T lymphocytes INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2004-01-08 US disclosed
US-6624151-B1 Concerns the uses of said compounds as selective inhibitors of T gamma 9 delta 2 lymphocytes, their uses, for therapeutic purposes. INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2003-09-23 US disclosed
EP-1165573-A1 COMPOUNDS SELECTIVELY INHIBITING GAMMA 9 DELTA 2 T LYMPHOCYTES INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2002-01-02 EP disclosed
WO-2000059916-A1 COMPOUNDS SELECTIVELY INHIBITING GAMMA 9 DELTA 2 T LYMPHOCYTES INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2000-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006131-A1 Compounds selectively inhibiting gamma 9 delta 2 T lymphocytes CD4, IL2RA, CD74 FDPS 2429/4885ALDH1A1 47/4885GRM4 4334/4885
US-20040009123-A1 Compounds selectively inhibiting gamma 9 delta 2 T lymphocytes CD4, IL2RA, CD74 FDPS 2429/4885ALDH1A1 47/4885GRM4 4334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.